Literature DB >> 3158702

Human neuroblastoma cell lines are susceptible to lysis by natural killer cells but not by cytotoxic T lymphocytes.

E K Main, L A Lampson, M K Hart, J Kornbluth, D B Wilson.   

Abstract

The susceptibility of human neuroblastoma cells to direct cellular cytotoxicity has not been previously established. This is of particular interest because of their aggressive growth and low HLA expression. Neuroblastoma lines CHP 100 and CHP 126 were found to be excellent targets in 4-hr CML assays. Natural killer (NK) cells from fresh PBL and from an NK clone, 3.3, have high lytic activity against both cell lines. We also studied mixed lymphocyte culture-generated cytotoxic lines containing allo-specific cytotoxic T lymphocytes (CTL) directed against HLA antigens present on the neuroblastoma target cell lines. These lines did show excellent lytic activity, but cold target competition studies indicated that all of the lysis resulted from NK activity. This was verified by using inhibition studies with the use of monoclonal antibodies. OKT 3 and anti-HLA antibodies that block CTL function caused no reduction in kill. In contrast, anti-lymphocyte function antigen-1 (anti-LFA-1), which blocks both NK and CTL function, significantly inhibited lysis. These results serve as a functional confirmation of earlier findings of a very weak expression of HLA-A,B,C and beta 2-microglobulin on neuroblastoma cells.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3158702

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  26 in total

1.  Licensed to kill.

Authors:  G Cambridge
Journal:  Br Med J (Clin Res Ed)       Date:  1986-10-11

2.  N-myc expression switched off and class I human leukocyte antigen expression switched on after somatic cell fusion of neuroblastoma cells.

Authors:  R Versteeg; C van der Minne; A Plomp; A Sijts; A van Leeuwen; P Schrier
Journal:  Mol Cell Biol       Date:  1990-10       Impact factor: 4.272

Review 3.  NK cell-based immunotherapies in Pediatric Oncology.

Authors:  Kimberly A McDowell; Jacquelyn A Hank; Kenneth B DeSantes; Christian M Capitini; Mario Otto; Paul M Sondel
Journal:  J Pediatr Hematol Oncol       Date:  2015-03       Impact factor: 1.289

4.  Augmentation of cell number and LAK activity in peripheral blood mononuclear cells activated with anti-CD3 and interleukin-2. Preliminary results in children with acute lymphocytic leukemia and neuroblastoma.

Authors:  P M Anderson; F H Bach; A C Ochoa
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

5.  Human neuroblastoma cell growth in xenogeneic hosts: comparison of T cell-deficient and NK-deficient hosts, and subcutaneous or intravenous injection routes.

Authors:  W J Turner; J Chatten; L A Lampson
Journal:  J Neurooncol       Date:  1990-04       Impact factor: 4.130

6.  Membrane-bound TRAIL supplements natural killer cell cytotoxicity against neuroblastoma cells.

Authors:  Michael A Sheard; Shahab Asgharzadeh; Yin Liu; Tsen-Yin Lin; Hong-Wei Wu; Lingyun Ji; Susan Groshen; Dean A Lee; Robert C Seeger
Journal:  J Immunother       Date:  2013-06       Impact factor: 4.456

Review 7.  More than the genes, the tumor microenvironment in neuroblastoma.

Authors:  Lucia Borriello; Robert C Seeger; Shahab Asgharzadeh; Yves A DeClerck
Journal:  Cancer Lett       Date:  2015-11-17       Impact factor: 8.679

8.  Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy.

Authors:  Yin Liu; Hong-Wei Wu; Michael A Sheard; Richard Sposto; Srinivas S Somanchi; Laurence J N Cooper; Dean A Lee; Robert C Seeger
Journal:  Clin Cancer Res       Date:  2013-02-01       Impact factor: 12.531

9.  Interferon-gamma-dependent infiltration of human T cells into neuroblastoma tumors in vivo.

Authors:  Gregor S D Reid; Xiaochuan Shan; Christina M Coughlin; Wiem Lassoued; Bruce R Pawel; Leonard H Wexler; Carol J Thiele; Maria Tsokos; Jack L Pinkus; Geraldine S Pinkus; Stephan A Grupp; Robert H Vonderheide
Journal:  Clin Cancer Res       Date:  2009-10-13       Impact factor: 12.531

10.  Expression of markers shared between human natural killer cells and neuroblastoma lines.

Authors:  R C McGarry; A Pinto; D R Hammersley-Straw; C L Trevenen
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.